| pubmed-article:8119423 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8119423 | lifeskim:mentions | umls-concept:C0005308 | lld:lifeskim |
| pubmed-article:8119423 | lifeskim:mentions | umls-concept:C0007389 | lld:lifeskim |
| pubmed-article:8119423 | lifeskim:mentions | umls-concept:C0814225 | lld:lifeskim |
| pubmed-article:8119423 | lifeskim:mentions | umls-concept:C0442183 | lld:lifeskim |
| pubmed-article:8119423 | pubmed:dateCreated | 1994-4-4 | lld:pubmed |
| pubmed-article:8119423 | pubmed:abstractText | Following cataract extraction, the intraocular inflammatory response is particularly marked in some patients, who then require more intensive post-operative care. This prospective randomised double-masked controlled trial of 246 patients undergoing cataract extraction assessed the efficacy and safety of a prophylactic subconjunctival injection of betamethasone (Betnesol, Glaxo) in improving the post-operative course. Betamethasone injected subconjunctivally at the end of cataract extraction significantly reduces anterior segment inflammation (p < 0.05) on the first post-operative day. It also reduces the need for additional steroid treatment and in-patient stay (p < 0.05). The benefits are most marked in those patients prone to a greater inflammatory response: especially those with previous intraocular inflammation (p < 0.01), but also those with racial pigmentation or difficult surgery. There was no evidence of adverse effects following betamethasone; in particular there was no endophthalmitis or steroid-induced elevation of intraocular pressure. We therefore conclude that subconjunctival injection of betamethasone is a practical, safe and effective means of improving the quality and efficiency of patient care. | lld:pubmed |
| pubmed-article:8119423 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8119423 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8119423 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8119423 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8119423 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8119423 | pubmed:issn | 0950-222X | lld:pubmed |
| pubmed-article:8119423 | pubmed:author | pubmed-author:ShillingJ SJS | lld:pubmed |
| pubmed-article:8119423 | pubmed:author | pubmed-author:BoultonJ EJE | lld:pubmed |
| pubmed-article:8119423 | pubmed:author | pubmed-author:CorbettM CMC | lld:pubmed |
| pubmed-article:8119423 | pubmed:author | pubmed-author:HingoraniMM | lld:pubmed |
| pubmed-article:8119423 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8119423 | pubmed:volume | 7 ( Pt 6) | lld:pubmed |
| pubmed-article:8119423 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8119423 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8119423 | pubmed:pagination | 744-8 | lld:pubmed |
| pubmed-article:8119423 | pubmed:dateRevised | 2009-11-3 | lld:pubmed |
| pubmed-article:8119423 | pubmed:meshHeading | pubmed-meshheading:8119423-... | lld:pubmed |
| pubmed-article:8119423 | pubmed:meshHeading | pubmed-meshheading:8119423-... | lld:pubmed |
| pubmed-article:8119423 | pubmed:meshHeading | pubmed-meshheading:8119423-... | lld:pubmed |
| pubmed-article:8119423 | pubmed:meshHeading | pubmed-meshheading:8119423-... | lld:pubmed |
| pubmed-article:8119423 | pubmed:meshHeading | pubmed-meshheading:8119423-... | lld:pubmed |
| pubmed-article:8119423 | pubmed:meshHeading | pubmed-meshheading:8119423-... | lld:pubmed |
| pubmed-article:8119423 | pubmed:meshHeading | pubmed-meshheading:8119423-... | lld:pubmed |
| pubmed-article:8119423 | pubmed:meshHeading | pubmed-meshheading:8119423-... | lld:pubmed |
| pubmed-article:8119423 | pubmed:meshHeading | pubmed-meshheading:8119423-... | lld:pubmed |
| pubmed-article:8119423 | pubmed:meshHeading | pubmed-meshheading:8119423-... | lld:pubmed |
| pubmed-article:8119423 | pubmed:meshHeading | pubmed-meshheading:8119423-... | lld:pubmed |
| pubmed-article:8119423 | pubmed:meshHeading | pubmed-meshheading:8119423-... | lld:pubmed |
| pubmed-article:8119423 | pubmed:meshHeading | pubmed-meshheading:8119423-... | lld:pubmed |
| pubmed-article:8119423 | pubmed:meshHeading | pubmed-meshheading:8119423-... | lld:pubmed |
| pubmed-article:8119423 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8119423 | pubmed:articleTitle | Subconjunctival betamethasone is of benefit after cataract surgery. | lld:pubmed |
| pubmed-article:8119423 | pubmed:affiliation | Department of Ophthalmology, Greenwich District Hospital, London, UK. | lld:pubmed |
| pubmed-article:8119423 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8119423 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8119423 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8119423 | lld:pubmed |
